Loading
A phase 2 trial of SPH5030 in colorectal cancer, run by Shanghai Pharmaceuticals Holding Co., Ltd, now recruiting.
A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. is a phase 2 interventional study registered as NCT06434597 by Shanghai Pharmaceuticals Holding Co., Ltd, with 60 participants planned, started 2024-07-17 and due to reach its primary completion in 2026-12-31. Interventions recorded: SPH5030.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares GenFleet Therapeutics and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares HER2-amplified colorectal cancer, Colorectal cancer and the tag pipeline.
Shares HER2-amplified colorectal cancer, Colorectal cancer and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares HER2-amplified colorectal cancer, Colorectal cancer and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/